Science Explorer Back to mapMap
Discussion
Researcher · Taiho Pharmaceutical (Japan) · Japan

Kaoru Funabashi

Kaoru Funabashi publishes mostly in Molecular Biology, Oncology and Pulmonary and Respiratory Medicine, on topics such as Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research and RNA modifications and cancer.

OpenAlex
World rank
#1,658,491
of 7,710,434 ranked researchers
Rank in Japan
#27,631
of 383,136
Works
34
Citations
676
Citations per work
19.9
h-index
10
i10-index 10Top 76% in Molecular Biology
Kaoru Funabashi

What does Kaoru Funabashi research?

Kaoru Funabashi's work is mostly in Medicine (50%), Biochemistry, Genetics and Molecular Biology (34%).

Health Sciences: 17 works · 50.0% of their workMedicine: 17 works · 50.0% of their workOncology: 7 works · 20.5% of their workPulmonary and Respiratory Medicine: 6 works · 18.2% of their workPhysiology: 2 works · 6.8% of their workRheumatology: 2 works · 4.5% of their workLife Sciences: 12 works · 34.1% of their workBiochemistry, Genetics and Molecular Biology: 12 works · 34.1% of their workMolecular Biology: 11 works · 31.8% of their workCell Biology: 1 works · 2.3% of their workEverything else: 5 works · 15.9% of their workTHEIR WORKKaoru Funabashi34works
Life Sciences34%Health Sciences50%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine1750.0%
    1. Biochemistry, Genetics and Molecular Biology1234.1%
  3. Everything else515.9%
  1. 1Molecular Biology32% of their works
  2. 2Oncology20% of their works
  3. 3Pulmonary and Respiratory Medicine18% of their works
  4. 4Physiology7% of their works
  5. 5Rheumatology4% of their works
  6. 6Cell Biology2% of their works

Research topics

Which keywords describe Kaoru Funabashi's research?

The keywords of their largest research topics: Clinical Trials, Targeted Therapy, ALK Inhibitors, EGFR Mutations, Chemotherapy, Breast Cancer, HER2 and Cancer.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 21 words, with their numbers
  1. Clinical Trials102 topics
  2. Targeted Therapy102 topics
  3. ALK Inhibitors81 topic
  4. EGFR Mutations81 topic
  5. Chemotherapy72 topics
  6. Breast Cancer51 topic
  7. HER251 topic
  8. Cancer42 topics
  9. Signaling42 topics
  10. Crystal Structure21 topic
  11. Endothelial Dysfunction21 topic
  12. FGF2121 topic
  13. Fibroblast Growth Factor21 topic
  14. G-Protein-Coupled Receptors21 topic
  15. Genomic Profiles21 topic
  16. Nitric Oxide21 topic
  17. PI3K/AKT pathway21 topic
  18. RNA methylation21 topic
  19. Small-Cell Lung Cancer21 topic
  20. m6A-seq21 topic
  21. mTOR21 topic

Where does Kaoru Funabashi work?

Kaoru Funabashi's main affiliation in the publication record is Taiho Pharmaceutical (Japan), Japan.

How many publications and citations does Kaoru Funabashi have?

OpenAlex counts 34 works and 676 citations for Kaoru Funabashi, an h-index of 10, ranking #1,658,491 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Kaoru Funabashi. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.